The LODESTAR study is evaluating the response of the rucaparib in people with advanced (including breast, ovarian, pancreatic, and other cancers) who have an or an acquired mutation in any of the following genes: , , , , , , , FANCA, , RAD51 or RAD51B. NOTE: This study is no longer enrolling people.

This Study is Open To:

NOTE: This study is no longer enrolling people.

This Study is NOT Open To:

NOTE: This study is no longer enrolling people.

Study Contact Information:

Principal Investigator:

Kim Reiss-Binder, MD

University of Pennsylvania

Study Contact Information:

A Study to Evaluate Rucaparib in Patients with Solid Tumors and with Deleterious Mutations in HRR Genes (LODESTAR)

Study Contact Information:

About the Study

This Study is Open To:

This Study is NOT Open To:

Study Contact Information:

Knowledge Can Save Lives